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Abstract
Brazil is expected to have 19.6 million patients with diabetes by the year 2030. A key concept in the treatment of type 2
diabetes mellitus (T2DM) is establishing individualized glycemic goals based on each patient’s clinical characteristics,
which impact the choice of antihyperglycemic therapy. Targets for glycemic control, including fasting blood glucose,
postprandial blood glucose, and glycated hemoglobin (A1C), are often not reached solely with antihyperglycemic
therapy, and insulin therapy is often required. Basal insulin is considered an initial strategy; however, premixed insulins
are convenient and are equally or more effective, especially for patients who require both basal and prandial control but
desire a more simplified strategy involving fewer daily injections than a basal-bolus regimen. Most physicians are
reluctant to transition patients to insulin treatment due to inappropriate assumptions and insufficient information. We
conducted a nonsystematic review in PubMed and identified the most relevant and recently published articles that
compared the use of premixed insulin versus basal insulin analogues used alone or in combination with rapid-acting
insulin analogues before meals in patients with T2DM. These studies suggest that premixed insulin analogues are equally
or more effective in reducing A1C compared to basal insulin analogues alone in spite of the small increase in the risk of
nonsevere hypoglycemic events and nonclinically significant weight gain. Premixed insulin analogues can be used in
insulin-naïve patients, in patients already on basal insulin therapy, and those using basal-bolus therapy who are
noncompliant with blood glucose self-monitoring and titration of multiple insulin doses. We additionally provide practical
aspects related to titration for the specific premixed insulin analogue formulations commercially available in Brazil.
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Introduction
In 2011, the prevalence of diabetes mellitus worldwide
was approximately 366 million people [1]. In Central and
South America, it has been estimated that 25.1 million
people have diabetes [1]. Approximately 12.4 million
adults (20–79 years of age) in Brazil had diabetes in
2011; this is expected to increase to 19.6 million by 2030
[1]. In keeping with this epidemic, there have been a
growing number of cases in younger individuals with
longer life expectancies, many of whom will require
treatment with exogenous insulin [1].
The United Kingdom Prospective Diabetes Study
(UKPDS) comparing intensive treatment with conven-
tional treatment in patients with type 2 diabetes mellitus
(T2DM) showed that appropriate glycemic control signifi-
cantly reduces the rate of microvascular complications,
such as retinopathy, nephropathy, and neuropathy [2],
which persisted in the long-term follow-up to this study
[3]. Appropriate blood glucose (BG) control is also im-
portant for cardiovascular disease (CVD) [4], although the
reduction of CVD requires a multifactorial approach: con-
trol of blood pressure, lipid profile, and body weight;
smoking cessation; and regular aerobic exercise [5].
In order to control BG levels, medical associations,
such as the American Diabetes Association (ADA), the
European Association for the Study of Diabetes (EASD),
the American Association of Clinical Endocrinologists
(AACE), the American College of Endocrinology (ACE),
and the Brazilian Diabetes Society, recommend that diet
and lifestyle changes, increased physical activity, and
treatment with metformin be implemented soon after
diagnosis. Usually there is an improvement of glycemic
control for a period of time, depending on the patient’s
age, clinical condition, comorbidities, etc., but if it still
remains inadequate or there is progressive deterioration,
then the addition of other antihyperglycemic agents
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(AHAs) is usually necessary [6-11]. The combination of
2 or 3 noninsulin AHAs with different mechanisms of
action is frequently used, since most patients are reluc-
tant to start insulin. Moreover, patients with T2DM are
sometimes able to maintain endogenous insulin secre-
tion even in later stages of the disease [12]. If a patient
has not reached the desirable glycemic control goals or
presents signs that are related to low insulin action, such
as catabolic features (e.g., weight loss and/or ketonuria)
or persistent high levels of BG (>300-350 mg/dL), then
insulin therapy is recommended [8]. Several strategies
for insulin therapy in addition to oral AHAs can be
used: neutral protamine Hagedorn (NPH) insulin, basal
insulin analogues (detemir or glargine), or premixed
insulins.
Recent studies suggest that premixed insulin analogues
are more effective in reducing glycated hemoglobin
(A1C) than basal insulin analogues used alone [13-19].
However, premixed analogues tend to cause a small in-
crease in the risk of nonsevere hypoglycemic events and
a small, not clinically significant weight gain [13-19]. In
general, premixed insulin analogues are options for pro-
viding basal and prandial insulin in a simple, less com-
plicated way than the basal-bolus approach, and they
can be used in insulin-naïve patients. Advantages of this
regimen include the need for fewer BG measurements
during the day while ensuring that the patient receives
both basal insulin and bolus insulin at meals with 2 or a
maximum of 3 injections per day [13,20].
The aim of this nonsystematic overview is to discuss
barriers to insulin initiation, individualized treatment
goals, and recent studies that compared the use of
premixed insulin versus basal insulin analogues used
alone or in combination with rapid-acting insulin ana-
logues before meals in patients with T2DM. It also aims
to provide practical aspects of insulin treatment that can
be used to encourage and motivate patients to comply
with treatment and ultimately attain desirable glycemic
control.
A comprehensive literature search was conducted in
PubMed (1995 to 2012) using the search terms: type 2
diabetes mellitus, insulin, premixed, lispro, glycated
hemoglobin, biphasic insulin aspart, treatment goals, tar-
gets, and titration, to identify the most relevant and re-
cently published English language articles, including
reviews, meta-analyses, randomized trials, and treatment
guidelines related to these topics.
Barriers to insulin initiation
Most insulin-naïve patients and their physicians are reluc-
tant to transition to insulin treatment [21]. The reluctance
to begin insulin treatment comes from the perception that
the treatment regimen is complex; however, the decision
to start insulin may be based on insufficient information.
In a survey of insulin-naïve patients with poorly controlled
T2DM, who had been treated with 2 or more oral agents
and were recently prescribed insulin, the authors observed
that those failing to initiate prescribed insulin commonly
reported misconceptions and concerns regarding insulin
risk (35% of the patients believed that insulin causes
blindness, renal failure, amputations, heart attacks,
strokes, or early death), injections (e.g., injection phobia),
hypoglycemia, and impact on social life and work [22].
Nonadherent patients frequently felt their health care pro-
vider had not adequately explained the risks and benefits
of insulin. Insulin adherence may be improved through
better provider communication regarding risks, shared
decision making, and insulin self-management training.
Intensification of insulin therapy is often required in
patients with T2DM. The standard for intensive care
consists of the combination of basal insulin with a pre-
prandial insulin (rapid-acting) basal-bolus. However,
premixed insulin analogues are more convenient and
equally or more effective, despite being potentially asso-
ciated with slightly greater weight gain and nonsevere
hypoglycemic reactions [7,10,11,13,23-26].
Treatment goals per patient profiles
A key concept in the treatment of T2DM is establishing
individualized glycemic goals [9]. Targets for glycemic
control, including fasting BG (FBG), postprandial BG,
and A1C as well as lipid and blood pressure levels,
should be identified by the physician and the patient and
ultimately achieved by therapeutic means. A1C reflects
average BG over the previous 3 months [27], and it is a
strong predictor of diabetic microvascular complications
(retinopathy, neuropathy, and nephropathy) [28,29]. The
baseline A1C in patients with T2DM guides the phys-
ician in establishing the initial therapeutic approach and
is also used as a reference for adjusting the therapy
thereafter.
The A1C treatment target is established by taking into
account the balance needed between the level of BG
control, the patient’s risk of chronic complications, the
risk of treatment-related adverse events, and patient-
related psychosocioeconomic factors [9]. Thus, routine
check-ups are recommended twice a year for patients
meeting treatment goals and quarterly (every 3 months)
for all patients with T2DM whose therapy has been re-
cently modified or who are not meeting their glycemic
goals [7,10,11,30].
The role of FBG and postprandial BG in hypergly-
cemia remains controversial. A1C is a function of FBG
and postprandial BG, but the percentages and conditions
under which each of these components contributes to
A1C values have remained largely unknown. A study by
Monnier et al. [31] suggests that postprandial BG is the
main contributor to the metabolic disequilibrium in
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those patients with mild or moderate hyperglycemia. In
contrast, FBG is the main contributor to daytime hyper-
glycemia in those patients with poor glycemic control
(A1C >8.4%) [31]. Table 1 presents suggested values for
FBG and postprandial BG and their corresponding A1C
levels based on the results of this study. A recent study
[32] found that FBG area under the concentration-time
curve (AUC) predominated at all A1C quartiles and that
there were lower decreases in FBG and FBG AUC in pa-
tients above the A1C target. This finding suggests that
patients required a higher insulin dose or needed to be
switched to a more intensive treatment.
Another recent study [33], which reviewed strategies
of intensification of glucose control with different treat-
ment options for T2DM, concluded that the type of
treatment used to achieve glycemic control can focus on
FBG or postprandial BG. These findings suggest that if
lowering FBG is the treatment goal (basal insulin), then
FBG would contribute to approximately 34% of A1C
(mean value 7.7%) and postprandial BG to approximately
66% of A1C. If lowering postprandial BG is the treat-
ment goal (intensifying insulin treatment with premixed
insulin or adding prandial insulin), then FBG would
contribute to approximately 68% of A1C (mean 7.7%)
and 32% of postprandial BG [33]. Thus, it is important
to bear in mind that in order to normalize glycemic
exposure, attention must be paid to both basal and post-
prandial glucose excursions.
Due to the results obtained from the UKPDS, the
ADA and AACE recently agreed that the glycemic target
for most patients with T2DM should be A1C ≤6.5% or
≤7% [2,7,11]. However, recent studies have found that
intensive treatment does not lead to a reduction in new
CVD or reduced mortality in patients with a prior his-
tory of CVD [34,35]. In fact, the Action to Control Car-
diovascular Risk in Diabetes (ACCORD) trial reported
increased mortality in patients with T2DM over an aver-
age of 10 years and an increase in several risk factors for
CVD when patients were treated with the objective of
maintaining A1C levels close to the reference values [36].
Thus, an important consideration is how to balance the
potential benefits of intensive control with the risk of such
intensive targets. In that context, patients’ clinical and psy-
chosocial characteristics are key factors in the modifica-
tion of the glycemic targets.
Riddle [37] recently commented on the clinical impli-
cations stemming from the ACCORD trial results. The
main question is how to determine which patients are at
greater risk of death if undergoing intensive treatment.
It appears that patients with A1C values >8.5% and those
with limited A1C-lowering response after the first 12
months of treatment may be at higher risk. Riddle con-
cluded that, based on the ACCORD study results, gly-
cemic targets should be individualized and current
therapies adapted to each patient’s needs.
Clinical conditions that might impact the choice of insulin
therapy
In order to set glycemic goals for the management of
hyperglycemia in patients with T2DM, the treating phys-
ician must consider various important patient-specific
aspects that will impact the choice of insulin therapy,
such as age, presence of comorbidities, duration of
diabetes, presence of microvascular disease, history of
severe hypoglycemia, and psychosocial and economic
contexts. The recently published ADA and EASD [8]
position statement also reinforces this strategy as a good
practice when dealing with T2DM in naturalistic clinical
practice as part of individualizing therapy for the
patient.
Premixed insulin
Premixed analogues provide both basal and postpran-
dial coverage starting with 1 injection, but they are
generally administered twice daily (BID), 1 injection at
breakfast and 1 at supper. Physicians may recommend
adding further injections, depending on patient’s indi-
vidual needs [23,38-41].
In Brazil, there are currently 2 types of premixed insulins
available: human insulin and analogue insulin (Table 2).
Premixed human insulin consists of a basal component of
human insulin (70%) and a prandial component of un-
modified regular human insulin (30%) (HumulinW 70/30,
Eli Lilly and Company, Indianapolis, Indiana, USA;
NovolinW 70/30, Novo Nordisk, Princeton, NJ, USA).
Premixed insulin analogues have 2 components in
their formulation: the prandial component is a rapid-
acting analogue (either insulin lispro or aspart), and the
basal component is insulin lispro or aspart protamine sus-
pension. The rapid-acting analogue is also derived from
recombinant DNA, but with an amino acid modification
to make its action rapid, and an intermediate-acting
analogue derived from the addition of protamine. These
include insulin lispro mix 25 (LM25) (HumalogW
Mix25™, Eli Lilly and Company, Indianapolis, Indiana,
USA), insulin lispro mix 50 (LM50) (HumalogW Mix50™,
Table 1 Values of mean, fasting, and postprandial blood
glucose (BG) corresponding to glycated hemoglobin
(A1C) [31]
A1C (%) Mean
BG (mg/dL)
Fasting/preprandial
BG (mg/dL)
Postprandial
BG (mg/dL)
6.0 126 100 140
6.5 140 110 150
7.0 154 110 160
7.5 168 120 180
8.0 183 130 200
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Eli Lilly and Company, Indianapolis, Indiana, USA), insulin
aspart 70/30 (BIAsp 30) (NovoMixW 30, Novo Nordisk,
Princeton, NJ, USA), and insulin aspart 50/50 (NovoMixW
50, Novo Nordisk, Princeton, NJ, USA) (Table 2).
Premixed insulin analogues do not have 2 distinct
peaks [26,42-44]. Once absorbed, the time of action cor-
responds to the rapid onset of action, and the duration
of action corresponds to the intermediate insulin com-
ponent. The peak of action is unimodal, corresponding
to the maximum effect of rapid insulin, and it is steep
with a slow decline [42-44]. Their rapid absorption due
to the rapid component and the more pronounced onset
of insulin action means that these analogues can be
dosed immediately before or following a meal [26,43,44].
Glycemic monitoring
Using capillary glucose monitoring to adjust doses of
premixed insulin
Measurement of capillary glucose levels performed by
patients themselves (self-monitoring) is an important
tool in assessing BG levels and making the required ad-
justments to treatment to facilitate improved glycemic
control [45]. This helps the patients to better understand
the varying effects of nutrition, exercise, and stress on
their glycemic control [46]. It also allows patients to de-
tect hypoglycemia and to take corrective measures, such
as an insulin dose adjustment [46]. The required fre-
quency of self-monitoring depends on the patient’s disease
state, the treatment regimen, the target level of glycemic
control to be achieved, and physician judgment [47].
There are treatment regimens, such as those involving the
use of premixed insulin analogues, that allow less frequent
BG self-monitoring [7]. Various limitations of effective
home-based BG self-monitoring should be taken into
consideration. The major obstacles for effective self-
monitoring are the general lack of knowledge and training
of both patients and health care professionals regarding
its usefulness, appropriate technique, correct interpret-
ation of the data, appropriate medication adjustments and
diet or physical activity adjustments, as well as the
effect that BG self-monitoring can have on disease-
complication onset [7]. The Brazilian government aids
patients with diabetes by providing the equipment and
supplies (glucometer and glucose test strips) needed
for BG self-monitoring for patients who are using insu-
lin [48]. Therefore, comprehensive education programs
for health care professionals, patients, and patients’
support networks (family, close friends, and caregivers)
can help to overcome existing obstacles.
First step: preprandial monitoring
When initiating treatment with premixed analogue insulin
BID, it is recommended that patients measure BG just be-
fore breakfast and dinner as well as when there are symp-
toms consistent with hypoglycemia [13]. However, if the
patient has a snack midafternoon, it is recommended to
measure BG before the snack instead of before dinner be-
cause the carbohydrate content of the snack will influence
BG levels before dinner. When glycemic control is
achieved, measurements of BG can be performed less fre-
quently (preferably before breakfast, 1–2 times a week) to
confirm that adequate glycemic control is being maintained.
Approximately 3 months after reaching BG objectives,
measurement of A1C is recommended [7,10].
Second step: postprandial monitoring
In cases in which the established treatment goal has not
been achieved, it is suggested that paired measurements
of BG before and after main meals be performed to de-
fine when the use of corrective dietary measures and/or
a larger dosage of insulin is required. Whenever optimal
glycemic control is achieved, the patient might perform
less frequent BG measurements. It is important to note
that patients can achieve lower postprandial BG concen-
trations by reducing high glycemic index carbohydrates
(potatoes, white rice, white bread, white flour, white
pasta, polenta, etc.) in their diets [49].
Premixed insulin analogues
It is unclear which patients would most benefit from
the use of premixed analogues, but based on data
from a meta-analysis by Giugliano et al. [50] and the
DURAbility of Basal versus LM25 insulin Efficacy (DUR-
ABLE) study [51], it is possible to infer that certain pa-
tients would benefit more by starting insulin treatment
with premixed insulin analogues. Such patients include
those who have A1C around 8.5%, have higher elevations
Table 2 Insulin premixture formulations
Manufacturer Commercial
name
Composition
Eli Lilly and
Company
HumulinW 70/30 70% human insulin isophane
suspension, 30% regular
human insulin
HumalogW Mix25™ 25% insulin lispro, 75% insulin
lispro protamine suspension
HumalogW Mix50™ 50% insulin lispro, 50% insulin
lispro protamine suspension
Novo Nordisk NovolinW 70/30* 70% human insulin isophane
suspension, 30% regular
human insulin
NovoMixW 30 70% protamine-crystallized
insulin aspart and 30%
insulin aspart
NovoMixW 50* 50% protamine-crystallized
insulin aspart and 50%
insulin aspart
*Not available commercially in Brazil but still available in many other
countries; approved by the U.S. Food and Drug Administration and the
European Medicines Evaluation Agency.
Tambascia et al. Diabetology & Metabolic Syndrome 2013, 5:50 Page 4 of 10
http://www.dmsjournal.com/content/5/1/50
in postprandial glucose (difference between preprandial
and postprandial >50 mg/dL), are less capable or willing
to perform several measurements of self-monitored BG
during the day, and are able to eat regularly [51].
Whereas LM25 can be used for patients who have not
reached adequate postprandial BG concentrations (13,14,52),
LM50 can be used to enhance premixed insulin treatments
and is a good choice for patients who are already using
premixed analogues [53]. LM50 can also be an option for
those patients using basal insulin with multiple doses of
rapid insulin but who are not compliant with the treatment
regimen [20,54]. This higher premixed insulin can also be an
initial choice of treatment for patients who may need higher
daily doses of rapid insulin or those who eat meals with a
high carbohydrate content [18,53].
Indications to use premixed insulin analogues
Insulin-treatment-naïve patients
It is well established that patients with T2DM who do
not achieve glycemic goals despite lifestyle changes, in-
creased physical activity, and use of one or more AHAs
should start treatment with insulin [8,9]. The introduc-
tory type of insulin used depends on the degree of insu-
lin resistance and the amount of food consumed at each
meal [7,11,42]. In addition, recent evidence suggests that
LM25 provides similar glycemic control to that of insu-
lin lispro plus glargine in insulin-naïve patients with un-
controlled diabetes on AHAs [55]. Noninferiority of
insulin LM25 was demonstrated on a 0.4% margin for
glycemic control achieved with intensifying therapy in
such a patient group [55].
Once the physician has opted for a premixed insulin,
such as LM25 or BIAsp 30, insulin can be administered
initially at a dose of 10 U or 0.1 U/kg before breakfast.
The dose could then be titrated or repeated before dinner
on the following days, depending on individual needs
and eating patterns. Titration of insulin before breakfast
is based on BG before dinner, and titration before dinner
is based on BG before breakfast, as described in Table 3.
Insulin is adjusted every 3 days, according to the average
BG levels at the respective times [56].
If A1C is not below the pre-established goals at 4
months after insulin initiation, despite appropriate pre-
prandial BG, then postprandial BG should be assessed.
In these cases, if the patient does not receive insulin be-
fore lunch (as with a BID regimen), it is particularly im-
portant to measure BG 2 hours after lunch, as high
values may indicate the need to add a third dose of insu-
lin before this meal. Rapid-acting insulin or even an add-
itional dose of premixed insulin may be indicated if BG
before dinner is also above target goals (the choice of
the rapid proportion will depend on the amount of car-
bohydrates consumed in this meal) [49].
For patients whose main meal is dinner, a premixed in-
sulin analogue can be initiated with a single dose of 10 U
or 0.1 U/kg before dinner followed by an evaluation of the
effect on BG before breakfast. When the goal is achieved,
the insulin dose is maintained and A1C is assessed after 3
to 4 months. If A1C is not within the desired range, BG is
measured before dinner for a few days. If the values are
high, premixed insulin analogues can be initiated before
breakfast [10].
Patients already on basal insulin therapy
Some patients taking 1 daily dose of basal insulin (NPH,
detemir, or glargine) may not achieve the proposed A1C
targets due to postprandial hyperglycemia despite appropri-
ate fasting BG levels. In such cases, a prandial insulin can
be added or premixed analogues can be used. If the patient
was using basal or basal plus prandial insulin, then the total
daily insulin dose of the premixed analogue can be given
on a 1:1 basis, thus providing the same total daily dose as
before, with half the dose administered before breakfast
and the other half before dinner [56]. There are different
compositions of premixed insulin options, depending on
the amount of food consumed in each meal. The titration
process is as previously described (Table 3). If needed, gly-
cemic control may be improved with premixed insulin 3
times a day [8]. Premixed insulin for patients already on
basal insulin may offer greater capability to reduce A1C as
it would provide both fasting and prandial glucose coverage
with just 2 or 3 injections, whereas basal plus prandial in-
jections administered as separate formulations may require
more injections and increase the need for BG self-
monitoring.
However, we stress the fact that treatment needs to be
individualized based on the results of a recent compari-
son of BIAsp 30 with insulin glargine in patients with
T2DM who were not achieving glycemic targets on basal
Table 3 Algorithm for titration of premixed insulin‡ [56]
Preprandial blood glucose (mg/dL) Dose adjustment
<80 ↓ by 2
80-109 Maintain dose
110-139 ↑ by 2
140-179 ↑ by 4
≥180 ↑ by 6
‡This algorithm targets preprandial glucose ≤110 mg/dL to achieve a target
A1C <7%, and can be used for patients using premixed insulin twice daily
(BID) and 3 times daily (TID), including 3-day average blood
glucose measurements.
If BID - Adjust morning insulin dose based on the average predinner blood
glucose and evening insulin dose based on the average prebreakfast/fasting
blood glucose.
If TID - Adjust morning insulin dose based on prelunch glucose levels, lunch
insulin dose based on predinner glucose levels, and evening insulin dose
based on prebreakfast/fasting glucose level.
Do not increase dose in case of hypoglycemia (blood glucose <70 mg/dL) or
its symptoms.
Tambascia et al. Diabetology & Metabolic Syndrome 2013, 5:50 Page 5 of 10
http://www.dmsjournal.com/content/5/1/50
insulin or AHAs [57]. Findings of a large improvement
in the glargine group suggest that remaining on basal in-
sulin and truly optimizing the dose might be equally
beneficial for some patients.
Patients using basal-bolus insulin who are noncompliant with
BG self-monitoring and titration of multiple insulin doses
For patients on intensive insulin treatment but who are
noncompliant due to treatment complexity, do not fol-
low BG self-monitoring, or do not feel confident with ti-
tration of multiple insulin doses, the use of thrice-daily
(TID) premixed insulin, with a balanced composition of
rapid and intermediate or longer-acting insulin, is the
most appropriate strategy [25]. BG self-monitoring for
an intensive treatment, such as basal-bolus insulin, in-
cludes at least 6 measures a day (before and after the
most important meals), which could be more, depending
on the amount of carbohydrate of an extra meal during
the day [8,10]. To enable adequate titration of premixed
insulin, the recommendation for BG self-monitoring is one
measurement taken before each meal injection [14,20]. As
seen in the study by Rosenstock et al. [20], although the
noninferiority of premixed insulins versus basal-bolus ther-
apy was not demonstrated, a larger proportion of patients
treated with basal-bolus therapy achieved A1C targets
of <7% (54% versus 69%, p = 0.009) and ≤6.5% (35%
versus 50%, p = 0.01). For patients who have not
achieved fasting BG target and are not able to increase
the dose of premixed insulin before dinner due to
hypoglycemia after dinner, it is suggested that they replace
the dinner dose of LM50 with a premixed insulin
containing a less rapid-acting component, and maintain
the same concentration of rapid and basal insulin before
breakfast and lunch if the goals for those time points have
been achieved [18,20].
Titrating premixed analogue insulins
According to major studies performed in patients with
T2DM using insulin premixtures [20,53,54,58-62], the ti-
tration schedule should take into account the number of
injections that the patient is receiving. In patients with
T2DM treated with LM25 BID, the dose should be ti-
trated every 3 to 4 days (twice a week), as shown in
Table 3. Patients treated with LM50 who are usually re-
ceiving TID doses should adjust the premixed insulin
dose every 3 to 4 days (twice a week), as shown in
Table 4.
When experiencing severe or recurrent hypoglycemia
early in the morning, after breakfast, or before dinner
with a TID premixed insulin analogue regimen, or after
breakfast and before lunch with a BID regimen, the
premixed insulin dose received before the hypoglycemic
event should be reduced by 10%-20%. Treatment regi-
mens of patients on concomitant AHAs should be
handled with caution because adjustments in AHA
doses may be required to reduce the incidence of
hypoglycemia when using premixtures [20,63]. To achieve
better glycemic control for patients who require a more tai-
lored approach, physicians may prefer to titrate the
premixed insulin according to the postprandial BG measure
to achieve a postprandial BG goal of <144 mg/dL (Table 4)
[54].
Managing oral antihyperglycemic agents
Patients treated with metformin are monitored in order
to detect increasing levels of creatinine. Typical contra-
indications for metformin use are kidney, heart, liver,
and lung failure. Secretagogue agents, such as sulfonyl-
ureas and glinides, can be maintained until a major
secretory failure develops and should be discontinued
when prandial insulin is introduced, since postprandial
insulin can usually be managed with a rapid-acting insu-
lin analogue or a premixed insulin preparation [63]. This
usually occurs when the patient has adequate BG con-
centrations at night and early morning, but experiences
daytime hyperglycemia, in which case treatment with in-
sulin only is recommended [10].
How to manage hypoglycemia and weight gain
One of the main limitations of insulin therapy and the
attainment of glycemic control is the weight gain associ-
ated with insulin treatment. It has been widely observed
in numerous human insulin and premixed insulin stud-
ies [64-66] and can seriously affect patient compliance
with treatment and thus, may adversely affect the prog-
nosis. In the UKPDS study [3], patients in the intensive
treatment cohort gained approximately 5 kg more than
those in the conventional treatment cohort during a
10-year follow-up period. Likewise, in other studies
evaluating intensive therapy versus conventional ther-
apy [34-36], weight gain was generally greater in pa-
tients treated with intensive therapy. The weight gain
associated with intensive therapy and improvement in
glycemic control has been attributed to multiple
Table 4 Algorithm for premixed insulin titration –
adjustment according to postprandial glucose [54]
Postprandial blood glucose (mg/dL) Dose adjustment (units)
144-179 ↑ by 1 unit
180-218 ↑ by 2 units
219-258 ↑ by 3 units
≥259 ↑ by 4 units
Postprandial adjustment: Adjust insulin dose administered in a given meal
according to the 3-day average capillary blood glucose after the meal;
postprandial was defined as <2 hours after the meal with a blood glucose
goal of <144 mg/dL.
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factors, such as the anabolic effect of insulin itself, re-
duction of glycosuria (conservation of glucose calories
previously excreted by the kidneys), reduced catabol-
ism rate, appetite increase, hypoglycemia therapy, and
defensive feeding to prevent hypoglycemia or simply
due to the fear of hypoglycemia [64,66,67].
In order to control weight gain, several strategies can
be employed. A reduction in insulin dose requirements
by increasing the patient’s sensitivity to insulin through
diet and exercise can be effective. Administration of in-
sulin in patterns that simulate physiologic insulin secre-
tion can also help control weight gain and can be
achieved with premixed insulin analogues, e.g., BIAsp 30
and LM. The continuation of metformin after insulin
initiation has been associated not only with weight re-
duction, lower levels of A1C, and lower insulin require-
ments but also with a higher risk of hypoglycemia [68].
The use of rapid-acting insulin analogues for the meal-
time bolus, which when combined with intermediate-
acting insulin, can reduce the risk of hypoglycemia and
the need for snacks between meals [56]. Nutritional
guidance with the purpose of encouraging patients to
eat meals low in carbohydrates and to eliminate high-
glycemic-index foods altogether from their diet, as well
as encouraging patients to maintain a physical activity
program, are also helpful in controlling weight gain.
Conclusions
This nonsystematic review provides a compilation of re-
cent data comparing the efficacy and safety of premixed
insulin analogues versus basal insulin analogues used
alone or in combination with rapid-acting insulin ana-
logues before meals in patients with T2DM.
Premixed insulin analogues provide both the basal and
prandial coverage in a single formulation, which may ex-
plain the better glycemic control achieved with BID and
TID dosing regimens with premixed analogues com-
pared with a basal only or basal-bolus approach. This
regimen also requires fewer BG measurements during
the day when compared with basal-bolus therapy, and
ensures that the patient receives both basal insulin and
bolus insulin at meals with 2 or a maximum of 3 injec-
tions per day [13,20].
Recent data from a meta-analysis [50] and the DUR-
ABLE trial [51], suggest that certain patients will benefit
more by starting insulin treatment with premixed insulin
analogues than others, e.g., patients who have A1C
values close to 8.5%, those who have higher elevations in
postprandial glucose (difference between preprandial
and postprandial >50 mg/dL), those who are less capable
of performing several measurements of self-monitored
BG during the day for whom a basal-bolus treatment
would be more complex to follow, and those who are
able to eat regularly. In addition, recent evidence
suggests that LM25 provides a similar clinical effect on
glycemic control compared with insulin lispro plus
glargine in insulin-naïve patients with uncontrolled dia-
betes on AHAs [55]. In patients who fail to achieve post-
prandial BG control with a basal insulin, premixed
analogues can be an option in order to achieve [13,52]
and maintain [51] overall glycemic control. Glycemic
control with insulin analogues may be improved using a
titration approach [20,56], and treatment needs should
be tailored to the individual [9,56].
Individualized glycemic goal setting and establishing
when and how to start insulin depend on 2 very im-
portant patient-specific aspects: clinical conditions (age,
duration of diabetes, presence of microvascular disease
and comorbidities, and risk of severe hypoglycemia), and
psychosocial/economic context. Glycemic targets can be
either more or less stringent from patient to patient [9].
Thus it is important to balance the potential benefits of
intensive control with the risk of such intensive targets.
Weight gain, a main limitation of insulin treatment,
can significantly affect patient treatment compliance. It
is possible to overcome the barriers and main obstacles
for patients and physicians when starting insulin treat-
ment by implementing comprehensive education pro-
grams for health care professionals [69], patients, and
patients’ support networks that can help empower them
and clarify concerns and false perceptions related to
T2DM treatment [70].
In summary, premixed insulin analogues may mitigate
barriers to initiating insulin therapy by providing options
for both basal and prandial coverage. It might be a good
alternative for people whose control is inadequate with
AHAs and/or basal insulin, particularly those patients with
postprandial hyperglycemia or high A1C. Similarly, insulin
premixes can be the appropriate choice for patients requir-
ing both components of treatment (basal and bolus) but
who have restrictions based on the complexity of the basal-
bolus regimen. As with any T2DM therapy, insulinization
with premixed analogue therapy should adapt to a patient’s
lifestyle, hypoglycemia risk, and other factors, and should
be individualized.
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